Výsledky vyhledávání - "Eric L Snyder"

Akademický článek

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Autor: Phaedra C Ghazi, Kayla T O'Toole, Sanjana Srinivas Boggaram, Michael T Scherzer, Mark R Silvis, Yun Zhang, Madhumita Bogdan, Bryan D Smith, Guillermina Lozano, Daniel L Flynn, Eric L Snyder, Conan G Kinsey, Martin McMahon

Publikováno v: eLife, Vol 13 (2024)

Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent U.S. Food and Drug Administration approval of covalent inhibitors of KRASG12C such as sotorasib or adagrasib, KRAS oncoproteins are important pharmacological ta

Externí odkaz: https://doaj.org/article/95323d71411b4fb5a507d99214305120

Zobrazit plný text záznamu

Akademický článek

An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma

Autor: Rediet Zewdu, Elnaz Mirzaei Mehrabad, Kelley Ingram, Pengshu Fang, Katherine L Gillis, Soledad A Camolotto, Grace Orstad, Alex Jones, Michelle C Mendoza, Benjamin T Spike, Eric L Snyder

Publikováno v: eLife, Vol 10 (2021)

Cancer cells undergo lineage switching during natural progression and in response to therapy. NKX2-1 loss in human and murine lung adenocarcinoma leads to invasive mucinous adenocarcinoma (IMA), a lung cancer subtype that exhibits gastric differentia

Externí odkaz: https://doaj.org/article/6480f1d0e1a849568a7cc19f30a0c0d1

Zobrazit plný text záznamu

Akademický článek

FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer

Autor: Soledad A Camolotto, Shrivatsav Pattabiraman, Timothy L Mosbruger, Alex Jones, Veronika K Belova, Grace Orstad, Mitchell Streiff, Lydia Salmond, Chris Stubben, Klaus H Kaestner, Eric L Snyder

Publikováno v: eLife, Vol 7 (2018)

Changes in cancer cell identity can alter malignant potential and therapeutic response. Loss of the pulmonary lineage specifier NKX2-1 augments the growth of KRAS-driven lung adenocarcinoma and causes pulmonary to gastric transdifferentiation. Here,

Externí odkaz: https://doaj.org/article/3b7d0675f48d4a07bf22e8d442f8e824

Zobrazit plný text záznamu

Akademický článek

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide.

Autor: Eric L Snyder, Bryan R Meade, Cheryl C Saenz, Steven F Dowdy

Publikováno v: PLoS Biology, Vol 2, Iss 2, p E36 (2004)

Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of metastatic ovarian cancer, results in a devastating 15%-20% survival rate. Therapeutics that restore genes inactivated during oncogenesis are

Externí odkaz: https://doaj.org/article/fab6022f0c6447b483b25ec9c98521cf

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání